Login to Your Account

In The Clinic NEWS
Under-the-radar biosimilars partners Formycon AG and Bioeq GmbH gained altitude by disclosing that they initiated a pivotal phase III trial of FYB201, a biosimilar of ranibizumab (Lucentis, Genentech Inc.), in patients with neovascular age-related macular degeneration (wet AMD).

Exelixis Inc.'s MEK-inhibitor cobimetinib, given in combination with Roche AG's Zelboraf, significantly improved OS vs. Zelboraf alone for previously untreated patients with unresectable locally advanced or metastatic melanoma.

HONG KONG – With a nod to proceed from the Korea Food and Drug Administration, Seoul-based Kainos Medicine Inc. is taking its Parkinson's disease candidate, KR-33493, into the clinic.

More In The Clinic Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: